Onflict of interestDr. Paar declares to be an employee of Sanofi-Aventis Germany. All other authors have attended advisory boards and have held lectures for bpV(phen) a number of pharmaceutical companies including Sanofi-Aventis.Authors’ contributionsAll authors have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data. PB has drafted the manuscript. The other authors revised the manuscript for important intel-Page 7 of(page number not for citation purposes)Cardiovascular Diabetology 2008, 7:http://www.cardiab.com/content/7/1/lectual content. All authors have given final approval of the version to be published.17.AcknowledgementsThe AdaPT investigation is a project of the Germany Hypertension League. It is supported by an unrestricted educational grant by Sanofi-Aventis Germany, Berlin. Committee chair: Prof. Dr. Zidek, Berlin. Committee members: Prof. Dr. Schrader, Cloppenburg, Prof. Dr. Matthaei, Quakenbr k, Prof. Dr. Hasslacher, Heidelberg, Prof. Dr. Hoyer, Marburg, PD Dr. Paar, Berlin (without voting right).18.
Cardiovascular DiabetologyOriginal investigationBioMed CentralOpen AccessPrevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjectsOdd Erik Johansen*, Ellen Brustad, Steve Enger and Arnljot TveitAddress: Medical department, Asker and Baerum Hospital, PO Box 83, 1309 Rud, Norway Email: Odd Erik Johansen* – [email protected]; Ellen Brustad – [email protected]; Steve Enger – [email protected]; Arnljot Tveit – [email protected] * Corresponding authorPublished: 28 September 2008 Cardiovascular Diabetology 2008, 7:28 doi:10.1186/1475-2840-7-Received: 12 August PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27725455 2008 Accepted: 28 SeptemberThis article is available from: http://www.cardiab.com/content/7/1/28 ?2008 Johansen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.AbstractBackground: The prevalence of atrial fibrillation (AF) is increasing world wide and amongst factors that aggravate the risk is diabetes mellitus (DM), also in epidemic development. However, although DM is a potentially modifiable risk factor for AF, few, if any, studies have explored the prevalence of undiagnosed dysglycaemia among subjects with AF or if duration of AF are related to parameters of glycaemia or dysglycaemia prevalence. Methods: In this case control study, amongst 75-year old subjects with and without AF, the prevalence of dysglycaemia, i.e., impaired fasting glycaemia, impaired glucose tolerance or DM, according to World Health Organisation criteria was assessed by a 75-g oral glucose tolerance test (OGTT). Results: Prevalence of undiagnosed DM among the 108 subjects (male/female 73/35, BMI 25.4 ?3.2) without and the 46 (male/female 34/12, BMI 25.3 ?3.7) with AF (median AF duration five years) where 3.7 and 13.0 , respectively (p = 0.031, Odds ratio (OR) 3.86 (95 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/24646699 Confidence interval [CI]: 1.01, 16.25)) whereas the overall prevalence of dysglycaemia (prediabetes and DM) where similar (respectively 43.5 and 39.1 , p = 0.46, OR 0.83 [95 CI: 0.41, 1.69]). Patients with AF duration 5 years had however a higher dysglycaemia prevalence (61.1 [DM 22.2 , prediabetes 38.9 ]) as compared to AF duration < 5 yea.
